Skip to main content

Gan & Lee Pharmaceuticals

Gan & Lee Pharmaceuticals Co Ltd is a Chinese biopharmaceutical enterprise manufacturing recombinant human insulin analogs and diabetes care products globally. The company formulates and manufactures long-acting glargine (Basalin), rapid-acting lispro (Prandilin), and aspart insulin analogs, alongside reusable medical injection pens. Principal revenues are generated through product sales of insulin prescription drugs directly to medical distributors, hospital networks, and retail pharmacies across China and export destinations. Core end markets encompass diabetic patients, endocrinology clinics, hospital departments, and prescription pharmacies in China, Latin America, and emerging markets. Gan & Lee Pharmaceuticals holds a market-leading domestic position in China as a premier producer of domestic recombinant human insulin analogs. The company is headquartered in Beijing, China, and its common shares trade on the Shanghai Stock Exchange.

2 of the funds FundTelligence covers report a position in Gan & Lee Pharmaceuticals.

Sector
Health Care
Country
China
Funds holding it
2

Funds holding Gan & Lee Pharmaceuticals

Loading...